141 related articles for article (PubMed ID: 38604728)
21. Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayra YM; Al-Saraireh RA; Al-Muhaisen GH; Al-Mahdy YS; Al-Kharabsheh AM; Abufraijeh SM; Alrawashdeh HM
Curr Oncol; 2021 Sep; 28(5):3573-3584. PubMed ID: 34590601
[TBL] [Abstract][Full Text] [Related]
22. The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
Zheng L; Li X; Gu Y; Lv X; Xi T
Breast Cancer Res Treat; 2015 Feb; 150(1):105-18. PubMed ID: 25701119
[TBL] [Abstract][Full Text] [Related]
23. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid.
Zöllner A; Dragan CA; Pistorius D; Müller R; Bode HB; Peters FT; Maurer HH; Bureik M
Biol Chem; 2009 Apr; 390(4):313-7. PubMed ID: 19090726
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells.
Zheng L; Guo Q; Xiang C; Liu S; Jiang Y; Gao L; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Wang Y; Li X; Xi T
J Hematol Oncol; 2019 Mar; 12(1):23. PubMed ID: 30832689
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H- benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1:
Kowalski JP; Pelletier RD; McDonald MG; Kelly EJ; Rettie AE
Xenobiotica; 2021 Aug; 51(8):901-915. PubMed ID: 33993844
[TBL] [Abstract][Full Text] [Related]
26. Exploring human CYP4 enzymes: Physiological roles, function in diseases and focus on inhibitors.
Zhou M; Li J; Xu J; Zheng L; Xu S
Drug Discov Today; 2023 May; 28(5):103560. PubMed ID: 36958639
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients.
Al-Saraireh YM; Alshammari FOFO; Youssef AMM; Al-Sarayreh S; Almuhaisen GH; Alnawaiseh N; Al-Shuneigat JM; Alrawashdeh HM
Onco Targets Ther; 2021; 14():5249-5260. PubMed ID: 34803385
[TBL] [Abstract][Full Text] [Related]
28. Conditional regulation of the human CYP4X1 and CYP4Z1 genes.
Savas U; Hsu MH; Griffin KJ; Bell DR; Johnson EF
Arch Biochem Biophys; 2005 Apr; 436(2):377-85. PubMed ID: 15797250
[TBL] [Abstract][Full Text] [Related]
29. Molecular Functionality of Cytochrome P450 4 (CYP4) Genetic Polymorphisms and Their Clinical Implications.
Jarrar YB; Lee SJ
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480463
[TBL] [Abstract][Full Text] [Related]
30. Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma.
Eun HS; Cho SY; Lee BS; Seong IO; Kim KH
Mol Med Rep; 2018 Dec; 18(6):4865-4876. PubMed ID: 30280198
[TBL] [Abstract][Full Text] [Related]
31. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
Bruno RD; Njar VC
Bioorg Med Chem; 2007 Aug; 15(15):5047-60. PubMed ID: 17544277
[TBL] [Abstract][Full Text] [Related]
32. CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD).
Osborne N; Leahy C; Lee YK; Rote P; Song BJ; Hardwick JP
Biochem Pharmacol; 2022 Jan; 195():114841. PubMed ID: 34798124
[TBL] [Abstract][Full Text] [Related]
33. Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation.
Hsu MH; Savas U; Griffin KJ; Johnson EF
Drug Metab Rev; 2007; 39(2-3):515-38. PubMed ID: 17786636
[TBL] [Abstract][Full Text] [Related]
34. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
35. Discovery of rubiarbonone C as a selective inhibitor of cytochrome P450 4F enzymes.
Choi YJ; Quan KT; Park I; Lee SJ; Kang KW; Na M; Kim SK
Arch Toxicol; 2018 Nov; 92(11):3325-3336. PubMed ID: 30259074
[TBL] [Abstract][Full Text] [Related]
36. Drivers and suppressors of triple-negative breast cancer.
Wu W; Warner M; Wang L; He WW; Zhao R; Guan X; Botero C; Huang B; Ion C; Coombes C; Gustafsson JA
Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34389675
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Immunobiology; 2022 Mar; 227(2):152174. PubMed ID: 34999392
[TBL] [Abstract][Full Text] [Related]
38. Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them.
Guo Z; Johnson V; Barrera J; Porras M; Hinojosa D; Hernández I; McGarrah P; Potter DA
Cancer Metastasis Rev; 2018 Sep; 37(2-3):409-423. PubMed ID: 30066055
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
Baston E; Leroux FR
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
[TBL] [Abstract][Full Text] [Related]
40. Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition.
Lehmann D; Nelsen J; Ramanath V; Newman N; Duggan D; Smith A
J Clin Pharmacol; 2004 Aug; 44(8):861-5. PubMed ID: 15286089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
